Overview

This trial is active, not recruiting.

Condition type 2 diabetes
Treatments metformin, benfluorex
Phase phase 2
Sponsor Fourth Military Medical University
Collaborator Shandong Xinhua Pharmaceutical Company Limited in China
Start date October 2007
End date September 2008
Trial size 240 participants
Trial identifier NCT00544518, bfls071012

Summary

Objective--- Benfluorex may have effects on the glucose control in type 2 diabetes while it improves hyperlipidemia. We sought to compare the impacts of benfluorex versus metformin on glucose control and insulin secretion in Chinese type 2 diabetic patients.

Research design and methods—--a 16-week, double-blind, multiple centers, random parallel controlled study is designed to compare the impact of benfluorex (150-450mg/day, provided by Shandong Xinhua Pharmaceutical Company Limited in China) on glucose control, insulin secretion and its safety with metformin in type 2 diabetic patients. 240 type 2 diabetic patients are to be recruited to receive benfluorex or metformin(1:1). HbA1c, plasma lipid level, insulin and glucose at 0', 30', 120' after a standard meal will be measured before and after treatment, while fasting and postprandial glucose measured 4 times regularly. The change of HbA1c from baseline to the end of treatment will taken as main efficacy criterion, as the changes of fasting and after standard meal glucose and insulin level and plasma lipid level will be taken as secondary criteria. All patient will be given safety monitor at prior and post treatment. Data management and statistical analysis will adopt DAS for Clinical Trial 2.0.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator)
Primary purpose treatment
Arm
(Experimental)
benfluorex
2 tablets with breakfast and dinner for the first four weeks, if necessary, increase 2 tablets with noon for the next time, one of 2 tablets is dummy tablet.
(Active Comparator)
metformin
2 tablets with breakfast and dinner for the first four weeks, if necessary, increase 2 tablets with noon for the next time

Primary Outcomes

Measure
The change of HbA1c from baseline to the end of treatment
time frame: 16 weeks

Secondary Outcomes

Measure
the changes of fasting and after standard meal glucose and insulin level and plasma lipid level
time frame: 16 weeks

Eligibility Criteria

Male or female participants from 18 years up to 70 years old.

Inclusion Criteria: - For inclusion in the study, participants will be;① Antidiabetic drugs naïve Type 2 diabetes mellitus(WHO standard) with diet control more than 2 weeks; ②or diagnosed Type 2 diabetes mellitus with no oral antidiabetic drugs more than 6months; ③or Type 2 diabetes mellitus treated with insulin secretagogues more than 1 month; all patients have HbA1c between 7.0-10.0% and fasting glucose between 7.0mmol/L~13.0mmol/L. - Ages Eligible for Study: 18 Years --70 Years, Genders:Both - BMI: 23~40kg/m2 - No using insulin before 3 months - Consent to do birth control to Women of child-bearing age - Volunteer to join and sign Information consent form Exclusion Criteria: - Patients with ketoacidosis、hyperglycemic hyperosmolar syndrome. - Patients with severe diabetic complications - Patient with acute cardiovascular diseases,acute cerebrovascular diseases,with Vitamin B12、folic acid and iron deficiency,with severe trauma or surgery,severe infection diseases. - Allergy to benfluorex or metformin - ALT、AST> 2 times of upper normal limit,Cr> upper normal limit. - Having used benfluorex within 3 months before recruiting. - Patients accepting steroid hormones or malignant tumor treatment - Patients with drug abuse or bibulous history. - Patients with severe unconscious low blood glucose history,severe mental illness history and family history - Severe hypertensive patients(SBP>160 mmHg,DBP>95mmHg) - Patient with pancreas diseases.

Additional Information

Principal investigator Ji qiuhe, Ph.D
Description During the whole study, patients meet a physician on a regular basis. Safety is assessed by adverse event spontaneous reporting、physical examination、recording of vital signs、laboratory tests and electrocardiogram at baseline and 16 week . Blood samples are collected for centralized measure of HbA1C and fasting serum insulin(FSI)、PSI1/2、PSI2 after an overnight fast in all patients,Body weight, supine and standing blood pressures and heart rate are measured at each clinical visit. Adverse events are rated as mild, moderate or severe by the investigators and assessed for any causal relationship to the study drugs. Patients are entitled to interrupt the treatment at any time during the study, and investigators can withdraw patients, in particular if they are inadequately controlled.
Trial information was received from ClinicalTrials.gov and was last updated in May 2008.
Information provided to ClinicalTrials.gov by Fourth Military Medical University.